Repros Therapeutics (RPRX -1%) says the FDA has scheduled a meeting to discuss the Phase 2 tests...

|About: Repros Therapeutics Inc. (RPRX)|By:, SA News Editor

Repros Therapeutics (RPRX -1%) says the FDA has scheduled a meeting to discuss the Phase 2 tests for its low dose oral Proellex treatment for endometriosis. The teleconference will be held during the last week of August.